Antitumor agents. XXXIV: Mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells.
The quassinoids bruceantin, brucein D, brucein E, bruceoside A, and brusatol significantly inhibited P-388 lymphocytic leukemic cell RNA and protein synthesis in tissue culture. However, DNA synthesis inhibition seemed to correlate more directly with the anti-neoplastic activity of these compounds in the in vivo P-338 survival system. In vitro, brusatol and bruceoside A marginally inhibited 10-day P-388 lymphocytic leukemia DNA polymerase, RNA polymerase, thymidylate synthetase, dihydrofolate reductase, phosphoribosyl pyrophosphate aminotransferase, and cathepsin protease activities. In vivo studies demonstrated similar inhibition and elevated cyclic AMP levels, correlating positively with the antineoplastic activity of individual compounds. Purine synthesis was inhibited drastically by brusatol in vivo, and one key inhibition site in purine synthesis was at phosphoribosyl pyrophosphate aminotransferase, the regulatory enzyme. Histone phosphorylation and ribonucleotide reductase activity also were inhibited marginally by brusatol.
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D002478:Cells, Cultured; D004273:DNA, Neoplasm / Q000378:metabolism*; D005900:Glaucarubin / Q000031:analogs & derivatives / Q000494:pharmacology*; D007942:Leukemia, Experimental / Q000201:enzymology / Q000378:metabolism*; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D011714:Pyrans / Q000494:pharmacology*; D036702:Quassins; D012334:RNA, Neoplasm / Q000378:metabolism*
D000972:Antineoplastic Agents, Phytogenic; D004273:DNA, Neoplasm; D011714:Pyrans; D036702:Quassins; D012334:RNA, Neoplasm; C020237:brusatol; C020236:bruceoside A; D005900:Glaucarubin